Concepts (131)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Myelodysplastic Syndromes | 12 | 2004 | 35 | 0.500 |
Why?
|
| Antiphospholipid Syndrome | 1 | 2003 | 4 | 0.240 |
Why?
|
| Bone Marrow | 9 | 1999 | 73 | 0.210 |
Why?
|
| Apoptosis | 8 | 1999 | 251 | 0.190 |
Why?
|
| Thrombosis | 1 | 2021 | 59 | 0.190 |
Why?
|
| Tumor Necrosis Factor-alpha | 4 | 2004 | 215 | 0.140 |
Why?
|
| Leukemia, Promyelocytic, Acute | 2 | 1998 | 4 | 0.130 |
Why?
|
| Tretinoin | 2 | 1998 | 14 | 0.130 |
Why?
|
| Interphase | 4 | 1990 | 5 | 0.120 |
Why?
|
| Blood Coagulation | 1 | 2011 | 21 | 0.100 |
Why?
|
| Genetic Testing | 1 | 2011 | 64 | 0.100 |
Why?
|
| Venous Thrombosis | 1 | 2011 | 42 | 0.090 |
Why?
|
| Pulmonary Embolism | 1 | 2011 | 59 | 0.090 |
Why?
|
| Hematopoietic Stem Cells | 4 | 1999 | 13 | 0.090 |
Why?
|
| Leukemia, Myeloid, Acute | 3 | 2000 | 44 | 0.090 |
Why?
|
| Antineoplastic Agents | 2 | 2004 | 218 | 0.090 |
Why?
|
| Biomarkers | 2 | 2011 | 689 | 0.080 |
Why?
|
| Lymphohistiocytosis, Hemophagocytic | 1 | 2008 | 8 | 0.080 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2000 | 290 | 0.080 |
Why?
|
| Humans | 22 | 2021 | 29337 | 0.070 |
Why?
|
| Cell Cycle | 3 | 1997 | 41 | 0.070 |
Why?
|
| Bromodeoxyuridine | 3 | 1997 | 6 | 0.070 |
Why?
|
| Antibodies, Monoclonal | 2 | 2004 | 260 | 0.070 |
Why?
|
| Proto-Oncogenes | 1 | 2004 | 4 | 0.060 |
Why?
|
| Thalidomide | 1 | 2004 | 5 | 0.060 |
Why?
|
| Arsenicals | 1 | 2004 | 8 | 0.060 |
Why?
|
| Oxides | 1 | 2004 | 12 | 0.060 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2004 | 75 | 0.060 |
Why?
|
| Male | 11 | 2011 | 15621 | 0.060 |
Why?
|
| Transcription Factors | 1 | 2004 | 156 | 0.060 |
Why?
|
| DNA-Binding Proteins | 1 | 2004 | 254 | 0.050 |
Why?
|
| Arthroplasty, Replacement, Knee | 1 | 2011 | 696 | 0.050 |
Why?
|
| Female | 9 | 2011 | 16197 | 0.050 |
Why?
|
| Prevalence | 1 | 2003 | 487 | 0.050 |
Why?
|
| Cytokines | 3 | 1999 | 347 | 0.050 |
Why?
|
| DNA, Neoplasm | 2 | 1998 | 25 | 0.050 |
Why?
|
| Pilot Projects | 3 | 2011 | 394 | 0.050 |
Why?
|
| Connective Tissue | 2 | 1996 | 25 | 0.040 |
Why?
|
| Transforming Growth Factor beta | 2 | 1996 | 123 | 0.040 |
Why?
|
| Middle Aged | 8 | 2011 | 9823 | 0.040 |
Why?
|
| Palliative Care | 1 | 2000 | 145 | 0.040 |
Why?
|
| Ecchymosis | 1 | 1998 | 2 | 0.040 |
Why?
|
| Cytarabine | 2 | 2000 | 9 | 0.040 |
Why?
|
| Aged, 80 and over | 5 | 2011 | 4851 | 0.040 |
Why?
|
| Adult | 4 | 2021 | 8601 | 0.040 |
Why?
|
| Idoxuridine | 1 | 1997 | 1 | 0.040 |
Why?
|
| Aged | 7 | 2011 | 9448 | 0.040 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 1996 | 22 | 0.040 |
Why?
|
| Cysteine Endopeptidases | 1 | 1996 | 9 | 0.040 |
Why?
|
| Severity of Illness Index | 1 | 2021 | 1113 | 0.040 |
Why?
|
| Leukemia, Myeloid | 2 | 1995 | 5 | 0.040 |
Why?
|
| Endopeptidases | 1 | 1996 | 29 | 0.040 |
Why?
|
| DNA | 3 | 1997 | 125 | 0.040 |
Why?
|
| Tumor Cells, Cultured | 2 | 1992 | 145 | 0.030 |
Why?
|
| Phenotype | 2 | 2011 | 355 | 0.030 |
Why?
|
| Cell Division | 3 | 1996 | 113 | 0.030 |
Why?
|
| Risk Factors | 2 | 2011 | 2443 | 0.020 |
Why?
|
| Cell Lineage | 2 | 2004 | 29 | 0.020 |
Why?
|
| Pedigree | 1 | 2011 | 77 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2011 | 145 | 0.020 |
Why?
|
| Amifostine | 2 | 2000 | 3 | 0.020 |
Why?
|
| Monosomy | 1 | 1990 | 1 | 0.020 |
Why?
|
| Leukemia, Monocytic, Acute | 1 | 1990 | 4 | 0.020 |
Why?
|
| Chromosome Deletion | 1 | 1990 | 28 | 0.020 |
Why?
|
| Preoperative Care | 1 | 2011 | 135 | 0.020 |
Why?
|
| Anticoagulants | 1 | 2011 | 100 | 0.020 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 1989 | 9 | 0.020 |
Why?
|
| Patient Selection | 1 | 2011 | 232 | 0.020 |
Why?
|
| Antigens, Neoplasm | 1 | 1989 | 37 | 0.020 |
Why?
|
| Nucleoproteins | 1 | 1988 | 1 | 0.020 |
Why?
|
| Superoxides | 1 | 1988 | 26 | 0.020 |
Why?
|
| Treatment Outcome | 3 | 2004 | 3478 | 0.020 |
Why?
|
| Fatal Outcome | 1 | 2008 | 59 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2011 | 441 | 0.020 |
Why?
|
| Cell Differentiation | 1 | 1988 | 146 | 0.020 |
Why?
|
| Disease Progression | 2 | 2004 | 787 | 0.020 |
Why?
|
| Chicago | 1 | 2011 | 865 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2011 | 679 | 0.020 |
Why?
|
| Macrophages | 2 | 1999 | 128 | 0.020 |
Why?
|
| DNA Fragmentation | 2 | 1996 | 7 | 0.020 |
Why?
|
| DNA Replication | 2 | 1996 | 12 | 0.020 |
Why?
|
| S Phase | 2 | 1999 | 10 | 0.020 |
Why?
|
| Interleukin-1 | 2 | 1996 | 78 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2011 | 1184 | 0.020 |
Why?
|
| Anemia, Refractory | 1 | 2004 | 2 | 0.020 |
Why?
|
| Cytogenetic Analysis | 1 | 2004 | 4 | 0.020 |
Why?
|
| Pancytopenia | 1 | 2004 | 2 | 0.020 |
Why?
|
| Chromosome Aberrations | 1 | 2004 | 15 | 0.020 |
Why?
|
| Infliximab | 1 | 2004 | 16 | 0.020 |
Why?
|
| MDS1 and EVI1 Complex Locus Protein | 1 | 2004 | 3 | 0.020 |
Why?
|
| Zinc Fingers | 1 | 2004 | 10 | 0.020 |
Why?
|
| Remission Induction | 1 | 2004 | 96 | 0.020 |
Why?
|
| Spleen | 1 | 2004 | 51 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2004 | 145 | 0.020 |
Why?
|
| Time Factors | 1 | 1988 | 1616 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2004 | 241 | 0.020 |
Why?
|
| Hematopoiesis | 2 | 1996 | 11 | 0.010 |
Why?
|
| Immunosuppressive Agents | 1 | 2004 | 132 | 0.010 |
Why?
|
| Acute Disease | 2 | 1995 | 226 | 0.010 |
Why?
|
| Patient Compliance | 1 | 2004 | 164 | 0.010 |
Why?
|
| Mitoxantrone | 1 | 2000 | 4 | 0.010 |
Why?
|
| Radiation-Protective Agents | 1 | 2000 | 3 | 0.010 |
Why?
|
| Anorexia | 1 | 2000 | 4 | 0.010 |
Why?
|
| Pentoxifylline | 1 | 2000 | 7 | 0.010 |
Why?
|
| Blood Cell Count | 1 | 2000 | 15 | 0.010 |
Why?
|
| Ciprofloxacin | 1 | 2000 | 29 | 0.010 |
Why?
|
| Hematologic Diseases | 1 | 2000 | 14 | 0.010 |
Why?
|
| Hypotension | 1 | 2000 | 27 | 0.010 |
Why?
|
| Dexamethasone | 1 | 2000 | 48 | 0.010 |
Why?
|
| Gastrointestinal Diseases | 1 | 2000 | 43 | 0.010 |
Why?
|
| Karyotyping | 1 | 1999 | 13 | 0.010 |
Why?
|
| In Situ Nick-End Labeling | 1 | 1999 | 16 | 0.010 |
Why?
|
| Prognosis | 1 | 2000 | 840 | 0.010 |
Why?
|
| Sialoglycoproteins | 1 | 1996 | 8 | 0.010 |
Why?
|
| Cysteine Proteinase Inhibitors | 1 | 1996 | 10 | 0.010 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 1 | 1996 | 14 | 0.010 |
Why?
|
| Caspase 1 | 1 | 1996 | 14 | 0.010 |
Why?
|
| Oligopeptides | 1 | 1996 | 30 | 0.010 |
Why?
|
| Leukemia | 1 | 1996 | 10 | 0.010 |
Why?
|
| Antigens, CD34 | 1 | 1996 | 14 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 1998 | 389 | 0.010 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 1996 | 42 | 0.010 |
Why?
|
| Biopsy | 1 | 1995 | 234 | 0.010 |
Why?
|
| Models, Biological | 1 | 1996 | 343 | 0.010 |
Why?
|
| Tritium | 1 | 1992 | 14 | 0.010 |
Why?
|
| Adolescent | 1 | 1999 | 2279 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 1992 | 437 | 0.010 |
Why?
|
| Metaphase | 1 | 1990 | 2 | 0.010 |
Why?
|
| Nucleic Acid Hybridization | 1 | 1990 | 11 | 0.010 |
Why?
|
| Chromosome Mapping | 1 | 1990 | 52 | 0.010 |
Why?
|
| Regeneration | 1 | 1989 | 27 | 0.010 |
Why?
|